Clinical Scorecard: Optimized Dosing of Brentuximab Vedotin Enhances Outcomes for Patients with Classic Hodgkin Lymphoma: Insights from a Single-Center Study in China

At a Glance

Key Highlights

• A-AVD regimen showed a 2-year PFS rate of 76.7% compared to 71.1% for ABVD.
• Higher doses of BV (≥1.15 mg/kg) significantly improved PFS in advanced-stage patients.
• A-AVD was associated with a higher rate of peripheral neuropathy (47.1% vs. 5.2% in ABVD).
• Overall survival rates were comparable between A-AVD and ABVD regimens.
• The study emphasizes the importance of maintaining sufficient BV dose intensity.

Guideline-Based Recommendations

Diagnosis

• Pathologically confirmed Classic Hodgkin Lymphoma by hematopathology review.

Management

• Incorporate brentuximab vedotin into chemotherapy regimens for improved disease control.

Monitoring & Follow-up

• Monitor for peripheral neuropathy and pulmonary toxicity during treatment.

Risks

• Consider the risk of dose-dependent pulmonary toxicity associated with bleomycin.

Patient & Prescribing Data

Adult patients (≥18 years) with untreated Classic Hodgkin Lymphoma.

Brentuximab vedotin has been incorporated into clinical guidelines and is associated with improved outcomes when administered at sufficient doses.

Clinical Best Practices

• Maintain sufficient dose intensity of brentuximab vedotin when clinically feasible.
• Proactively manage toxicity, particularly peripheral neuropathy.

Related Resources & Content

• Study on A-AVD vs ABVD in cHL